Tianyi Ma

Tianyi Ma


Research Focus & Metrics

Representative Publications

View All Publications
25 May 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ZYZiming Yuan
Ziming Yuan
HHHanqing Hu
Hanqing Hu
YZYihao Zhu
Yihao Zhu
WZWeiyuan Zhang
Weiyuan Zhang
QFQingxiao Fang
Qingxiao Fang
XWXishan Wang
Xishan Wang
Fibroblast activation protein alpha (FAP) is a marker of cancer-associated fibroblast, which is also expressed in cancer epithelial cells. However, the role of FAP in colorectal cancer (CRC) cells remains to be elucidated. Here we investigate the expression pattern of FAP in CRC tissues and cells to prove that FAP is upregulated in CRC cells. Loss- of and gain-of-function assays identified FAP promotes migration and invasion instead of an effect on cell proliferation. Microarray assays are adopted to identify the different expressed genes after FAP knockdown and gene set enrichment analysis (GSEA) is used to exploit the involved signaling pathway. Our works reveal FAP exerts a function dependent on NF-κB signaling pathway and FAP expression is associated with NF-κB signaling pathway in clinical samples. Our work shows FAP is secreted by CRC cells and soluble FAP could promote metastasis. To investigate the mechanism of FAP influencing the NF-κB signaling pathway, LC/MS is performed to identify the proteins interacting with FAP. We find that FAP binds to ENO1 and activates NF-κB signaling pathway dependent on ENO1. Blocking ENO1 could partially reverse the pro-metastatic effect mediated by FAP. We also provide evidences that both FAP and ENO1 are associated with CRC stages, and high levels of FAP and ENO1 predict a poor survival in CRC patients. In summary, our work could provide a novel mechanism of FAP in CRC cells and a potential strategy for treatment of metastatic CRC.

1 January 2020 in Hypertension
Verified
Journal Article
Open access
PDF file
PGPeng Gao
Peng Gao
Li LiLi Li
Li Li
XWXiao Wei
Xiao Wei
MWMiao Wang
Miao Wang
YHYangning Hong
Yangning Hong
ZZZhiming Zhu
Zhiming Zhu
Endothelial dysfunction is an early step to the progression of cardiovascular diseases in diabetes. Apart from their anti-diabetic action, DPP-4 (dipeptidyl peptidase-4) inhibitors also reduce cardiovascular events in diabetic patients. However, the underlying mechanism of the beneficial effect of DPP-4 inhibitor on endothelial function is still obscure. In this study, we intervened type 1 or 2 diabetic model mice with vildagliptin for 4 weeks and measured the vascular reactivity. We found that vildagliptin improved endothelium-dependent vasodilation in diabetic mice independent of GLP-1 (glucagonlike peptide-1), but this effect was blocked by a SIRT1 (Sirtuin 1) inhibitor, Ex527. Mechanistically, vildagliptin-activated Transient Receptor Potential Channel Vanilloid 4 (TRPV4) to promote extracellular calcium uptake in endothelial cells, which activated AMPK (AMP-activated protein kinase)/SIRT1 pathway to counteract hyperglycemia-induced endothelial reactive oxygen species generation and senescence. Vildagliptin directly binds to TRPV4 by forming a hydrogen bond, which is critical to vildagliptin-evoked endothelial calcium intake. Knockout or inhibition of TRPV4 erased the beneficial role of vildagliptin. In addition, activation of SIRT1 by SRT1720 improved endothelial function independent of TRPV4 and reduced TRPV4 transcription to maintain an appropriate calcium level. In summary, our findings prove that vildagliptin protects against hyperglycemia-induced endothelial dysfunction by activating TRPV4-meditaed Ca 2+ uptake, which helps to re-understand the mechanism of DPP-4 inhibitors and expand the therapeutic scope.

1 September 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
YZYuchen Zhong
Yuchen Zhong
TMTianyi Ma
Tianyi Ma
TQTianyu Qiao
Tianyu Qiao
HHHanqing Hu
Hanqing Hu
ZLZhengliang Li
Zhengliang Li
XWXishan Wang
Xishan Wang
Objective: To investigate the relationship between circulating tumor cells (CTCs) and their subpopulations and colorectal cancer (CRC). To explore the application of CTCs’ numbers and positive rates in the diagnosis and treatment of CRC, and to assess the effect of surgery on CTCs numbers and positivity. Methods: We identified CTCs using the CanPatrol technique after enrollment. Peripheral blood samples were collected from 74 CRC patients before anti-tumor treatment. CTCs can be divided into the following three phenotypes: epithelial CTCs (E-CTCs) (EpCAM+, Vimentin-), mesenchymal CTCs (M-CTCs) (EpCAM-, Vimentin+), and mixed CTCs (E/M-CTCs) (EpCAM+, Vimentin+). CTCs and the proportion of subtypes were statistically compared with clinicopathological characteristics. Results: The positive rate of M-CTCs was significantly higher in patients with tumor size ≥ 5 cm (85.7% vs 49.1%, P = 0.004) and carcinoembryonic antigen (CEA) > 5 ng/mL (83.3% vs 51.0% p = 0.024). Moreover, the T stage (T1 0, T2 33.3%, T3 59.4%, T4 100%, p < 0.0005) and TNM stage (stage I 11.8%, stage II 79.2%, stage III 64.3%, stage IV 100%, p < 0.0005) were correlated with the positive rate of M-CTCs. We also found that the proportion of M-CTCs was correlated with the T stage (p < 0.0005) and TNM stage (p=0.0200), but not with the N stage (p=0.6889). In survival analysis, M-CTCs > 1 were found associated with worse disease-free survival (p=0.007). After treatment, the number and proportion of CTCs and M-CTCs were significantly reduced. Conclusion: The positive rate of M-CTCs was associated with tumor size, T stage, TNM stage, vascular invasion, and CEA. As the disease progressed, the proportion of M-CTCs gradually increased, and the survival performance was worse in patients with a high positive rate of M-CTCs.

28 August 2023 in Environmental Technology & Innovation
Verified
Journal Article
Open access
YWYanyan Wang
Yanyan Wang
MZMeng Zhang
Meng Zhang
XKXiangke Kong
Xiangke Kong
TMTianyi Ma
Tianyi Ma
WCwengeng cao
wengeng cao
SLShenghua Liu
Shenghua Liu

1 June 2012
Verified
Conference Paper
Closed access
Lu ZhangLu Zhang
Lu Zhang
XJXinmin Jin
Xinmin Jin
TMTianyi Ma
Tianyi Ma
YTYibin Tong
Yibin Tong
The increasing wind power penetration brings new challenge for wind turbine to provide Low Voltage Ride-Through (LVRT) capability. Doubly Fed Induction Generator (DFIG) has been widely used in wind turbines; due to its cost-effective partially power rated of the converter and Variable-Speed Constant-Frequency (VSCF) operation. However, the DFIG system has two poorly damped poles and is sensitive to the grid disturbance. For the stator is directly connected to the grid, the symmetrical voltage dip results in a dc component in the stator-flux which reflects a serious oscillation in the synchronous reference frame. This transient stator-flux induces overvoltage and overcurrent in the rotor circuit. The paper analyzes the characteristic of the transient stator-flux under voltage dip. Based on the eigenvalues of the system matrix, the damping rates of the transient stator-flux are investigated. An improved control scheme of the Rotor Side Converter (RSC) is presented to accelerate the transient stator-flux damping rate. The proposed control improves the rotor current control performance and relieves the fluctuation of electromagnetic torque, dc-link voltage, stator current and rotor current. It is also beneficial to the fast reactive power support to the grid during voltage dip. The simulation results of a 1.5-MW DFIG system and experimental tests on a 90-kW DFIG rig validate the theoretical analysis and the feasibility of the proposed control scheme.

1 February 2021 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
TMTianyi Ma
Tianyi Ma
TQTianyu Qiao
Tianyu Qiao
ZYZiming Yuan
Ziming Yuan
GWGuiyu Wang
Guiyu Wang
RHRui Huang
Rui Huang
XWXishan Wang
Xishan Wang
Background: The identification of cancer-associated long noncoding RNAs and the investigation of their molecular and biological functions are important for understanding the molecular biology and progression of cancer. JAKMIP2-AS1 has not been reported in the literature, especially in the context of colorectal cancer. The aim of the present study was to examine the expression pattern of JAKMIP2-AS1 in colorectal cancer (CRC) and evaluate its biological role and clinical significance in tumor progression. Methods: JAKMIP2-AS1 expression was analyzed in 56 CRC tissues and nine CRC cell lines by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Overexpression and RNA interference (RNAi) approaches were used to investigate the biological functions of JAKMIP2-AS1. The effect of JAKMIP2-AS1 on proliferation was evaluated by CCK-8, colony formation, and EdU assays. Subcutaneous injection of cells was used to study proliferation in BALB/c nude male mice. Proliferation-related protein levels were examined by immunohistochemical analysis. Differences between groups were tested for significance using Student’s t-test (two-tailed). Results: JAKMIP2-AS1 was highly expressed in both CRC samples and cell lines compared with the corresponding normal counterparts. The upregulation of JAKMIP2-AS1 expression promoted the proliferation of colorectal cancer cells. Moreover, patients with high levels of JAKMIP2-AS1 expression had a relatively poor prognosis. Inhibition of JAKMIP2-AS1 by RNAi decreased the proliferation of CRC cells in vitro and impeded cell growth in vivo. Ki-67 and PCNA levels were affected by JAKMIP2-AS1 knockdown or overexpression in vivo. Conclusion: Our findings indicate that JAKMIP2-AS1 is significantly upregulated in CRC tissues and regulates CRC cell proliferation. Thus, JAKMIP2-AS1 may represent a new marker of poor prognosis and is a potential therapeutic target for CRC intervention.